Tagged with OP

Cyprus Christoforos Hadjikyprianou of the European University Cyprus, home to the island’s only state-of-the-art medical school, explains the institution’s unique value proposition and his vision for the future. Could you introduce yourself as well as European University Cyprus? “In the last decade-and-a-half we have made huge strides.” I am the University’s…

Spain With Spain now on the road to economic recovery following the ravages of the global financial crisis, multinational pharmaceutical companies are seeing the country as a top investment destination once more thanks to a much-improved market access scenario, high-quality but affordable manufacturing capabilities and an enviable human resource base. As…

Brexit Brexit, Brexit, Brexit. It’s all anyone can talk about and yet nobody can tell you with certainty what to expect. As the UK’s impending withdrawal from the European Union looms ever closer, industry professionals fervently speculate on how it will affect the country’s position as one of the world’s great…

UK Professor David Garway-Heath, a specialist in glaucoma, talks with us about the screening devices of the future, low awareness of glaucoma as a chronic disease and collaboration in training and establishing standards of care on a European level.   I see technology as the enabler that creates new possibilities. Imaging…

UK After 30 years in the cell therapy space, Dr Michael Leek founded TC BioPharm in Scotland. Within four years the company has forged major partnership deals and advanced its CAR T therapies towards the clinic. Developing allogeneic variants of Gamma Delta T Cells, TC BioPharm aims to become a global…

UK Philip Lews Williams, managing director of the UK affiliate of French ophthalmology specialist Théa, describes the evolution of the company’s engagement in the UK and his strategy for taking on the big players in eyecare. Laboratoires Théa entered the UK for the first time back in 2007 via a joint…

UK Craig Wallace established the UK affiliate of Santen, the Japanese ophthalmology company, in 2014. Wallace describes the journey Santen has been on so far in the UK, as well as his ambitions to contribute to its goal of becoming a leading global ophthalmology company by 2020.  You set up Santen’s…

3D Bioprinting With the US FDA approval of a 3D bioprinted drug in 2016, the floodgates have been opened for a new wave of innovative, personalized and customizable printed medicine.   Printing tailored medicine could simplify our supply chain dramatically. Martin Wallace, GSK   3D Bioprinting on the Rise Many healthcare and…

Global The global regulatory landscape for medical cannabis, showing the countries in which medical cannabis and cannabinoid treatments are legal / essentially legal, illegal but often unenforced, decriminalized, and illegal.   Made with Visme Infographic Maker   Click here to download our report on Canada’s world-leading medical cannabis industry

Europe The top spenders on pharma R&D in Europe for 2015 were Switzerland – which spent over EUR 6.5 billion – followed by Germany – which spent EUR 6.2 billion – and the UK – which spent EUR 5.8 billion.

Cannabis While many Canadian medical cannabis outfits cover the entire value chain, from research and development through to manufacturing and distribution, others – such as Canopy Health and Tetra Bio-Pharma – are taking their cues from the biotechnology industry and strictly focusing on clinical trials.   I believe that across the…

Pharma In May 2018, PharmaBoardroom’s readers were asked what they felt were the biggest new sources of disruption to the traditional pharma industry today. Options included 3D Bioprinting, blockchain storage, genomics and artificial intelligence. 3D Bioprinting As Figure 1 (below) shows, 11 percent of our survey respondents felt that 3D bioprinting…